IN2014DN07813A - - Google Patents
Info
- Publication number
- IN2014DN07813A IN2014DN07813A IN7813DEN2014A IN2014DN07813A IN 2014DN07813 A IN2014DN07813 A IN 2014DN07813A IN 7813DEN2014 A IN7813DEN2014 A IN 7813DEN2014A IN 2014DN07813 A IN2014DN07813 A IN 2014DN07813A
- Authority
- IN
- India
- Prior art keywords
- parameter
- bode
- copd
- prognosis
- pro
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 2
- 108010048233 Procalcitonin Proteins 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 2
- 102000034567 proadrenomedullin Human genes 0.000 abstract 2
- 108010012004 proadrenomedullin Proteins 0.000 abstract 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 abstract 2
- 238000004393 prognosis Methods 0.000 abstract 2
- 238000012502 risk assessment Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 abstract 1
- 108010004977 Vasopressins Proteins 0.000 abstract 1
- 102000002852 Vasopressins Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960003726 vasopressin Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to a method for the prognosis and/or risk assessment and/or monitoring of therapy and/or management of patients with COPD the method comprising the steps of: i) providing a sample of a bodily fluid from said patient, ii) determining in said sample the level of at least one biomarker, selected from the group consisting of pro-adrenomedullin (proADM), pronatriuretic peptide, pro-Vasopressin (proAVP) and Procalcitonin (PCT) or fragments thereof of at least 12 amino acids in length, iii) determining one, two or three of the BODE-index parameters body-mass index (BMI, parameter B), degree of airflow obstruction (FEVi, parameter O), dyspnea (parameter D) and exercise capacity (parameter E), iv) correlating said level of said at least one biomarker determined in step ii), in combination with said one, two or three BODE-index parameters determined in step iii) to the prognosis and/or risk assessment and/or monitoring of therapy and/or management of patients with COPD.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12001590.4A EP2637023A1 (en) | 2012-03-08 | 2012-03-08 | Prediction of outcome in patients with chronic obstructive pulmonary disease |
PCT/EP2013/000558 WO2013131621A1 (en) | 2012-03-08 | 2013-02-26 | Prediction of outcome in patients with chronic obstructive pulmonary disease |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN07813A true IN2014DN07813A (en) | 2015-07-10 |
Family
ID=47780019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN7813DEN2014 IN2014DN07813A (en) | 2012-03-08 | 2013-02-26 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150080246A1 (en) |
EP (3) | EP2637023A1 (en) |
JP (1) | JP6117251B2 (en) |
CN (1) | CN104126125B (en) |
BR (1) | BR112014019349A8 (en) |
DK (1) | DK2823314T3 (en) |
ES (1) | ES2631653T3 (en) |
HK (1) | HK1198556A1 (en) |
IN (1) | IN2014DN07813A (en) |
RU (1) | RU2688168C2 (en) |
WO (1) | WO2013131621A1 (en) |
ZA (1) | ZA201405610B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2637023A1 (en) | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
WO2016024278A1 (en) | 2014-08-14 | 2016-02-18 | Memed Diagnostics Ltd. | Computational analysis of biological data using manifold and a hyperplane |
CN106999097B (en) * | 2014-11-12 | 2021-05-11 | 皇家飞利浦有限公司 | Device and method for assessing the severity of chronic obstructive pulmonary disease, COPD, in a subject |
CA2986097A1 (en) | 2015-05-18 | 2016-11-24 | The University Of British Columbia | Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd |
US11466331B2 (en) | 2016-03-03 | 2022-10-11 | Memed Diagnostics Ltd. | RNA determinants for distinguishing between bacterial and viral infections |
CN107229813A (en) * | 2016-03-24 | 2017-10-03 | 深圳中迈数字医疗技术有限公司 | Implement the determination methods and system of monitoring |
CN109661578B (en) | 2016-07-10 | 2022-05-10 | 米密德诊断学有限公司 | Protein characterization for differentiating bacterial and viral infections |
EP4184167A1 (en) | 2016-07-10 | 2023-05-24 | MeMed Diagnostics Ltd. | Early diagnosis of infections |
US11353456B2 (en) * | 2016-09-29 | 2022-06-07 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification for appendicitis |
CN110431425B (en) * | 2017-02-02 | 2023-06-27 | B.R.A.H.M.S 有限公司 | ProADM as a marker for adverse events |
WO2018191560A1 (en) * | 2017-04-12 | 2018-10-18 | Proterixbio, Inc. | Biomarker combinations for monitoring chronic obstructive pulmonary disease and/or associated mechanisms |
CN107267658B (en) * | 2017-08-21 | 2018-11-02 | 常州市第二人民医院 | COPD diagnosis molecular markers |
EP3682246A1 (en) * | 2017-09-13 | 2020-07-22 | B.R.A.H.M.S GmbH | Method for guidance of fluid therapy based on proadrenomedullin |
EP3682236A1 (en) * | 2017-09-13 | 2020-07-22 | B.R.A.H.M.S GmbH | Proadrenomedullin as indicator for renal replacement therapy in critically ill patients |
BR112020004150A2 (en) * | 2017-09-13 | 2020-09-08 | B.R.A.H.M.S Gmbh | pct and pro-adm as markers to monitor antibiotic treatment |
EP3502706A1 (en) * | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
CN108424969B (en) * | 2018-06-06 | 2022-07-15 | 深圳市颐康生物科技有限公司 | Biomarker, method for diagnosing or predicting death risk |
CN109218131B (en) * | 2018-09-03 | 2022-03-29 | 平安医疗健康管理股份有限公司 | Network monitoring method and device, computer equipment and storage medium |
EP3914913A1 (en) * | 2019-02-21 | 2021-12-01 | B.R.A.H.M.S GmbH | Method for the diagnosis of macce in patients who underwent gastrointestinal surgery |
CN110850006B (en) * | 2019-12-20 | 2020-11-20 | 河南中医药大学 | Chronic obstructive pulmonary disease diagnostic reagent and kit |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
SI2019965T1 (en) * | 2006-05-02 | 2015-10-30 | Critical Care Diagnostics, Inc. | Differential diagnosis between pulmonary and cardiovascular disease |
DE102006046996A1 (en) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnosis process for respiratory infections involves using procalcitonin as marker for assessing patient risk level |
DE102006053442A1 (en) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnosis and risk stratification of infections and chronic diseases of the respiratory and lungs by means of proVasopressin, in particular copeptin or neurophysin II |
DE102006060112A1 (en) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnosis and risk stratification using the new marker CT-proADM |
US8815519B2 (en) * | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
DE102007021443A1 (en) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnosis and risk stratification using NT-proET-1 |
PT2269063E (en) * | 2008-04-18 | 2013-11-27 | Critical Care Diagnostics Inc | Predicting risk of major adverse cardiac events |
WO2010054810A1 (en) * | 2008-11-11 | 2010-05-20 | B.R.A.H.M.S Ag | Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp |
GB0911007D0 (en) * | 2009-06-25 | 2009-08-12 | Univ Hospital Of North Staffordshire | Analyzer apparatus and methods for lung disease |
CN102253220B (en) * | 2011-06-07 | 2014-04-09 | 复旦大学附属中山医院 | Kit used for diagnosing acute exacerbation period of chronic obstructive pulmonary disease |
EP2637023A1 (en) | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
-
2012
- 2012-03-08 EP EP12001590.4A patent/EP2637023A1/en not_active Withdrawn
-
2013
- 2013-02-26 RU RU2014140608A patent/RU2688168C2/en active
- 2013-02-26 EP EP17000604.3A patent/EP3232201A1/en active Pending
- 2013-02-26 CN CN201380009139.6A patent/CN104126125B/en active Active
- 2013-02-26 US US14/383,744 patent/US20150080246A1/en not_active Abandoned
- 2013-02-26 WO PCT/EP2013/000558 patent/WO2013131621A1/en active Application Filing
- 2013-02-26 JP JP2014560266A patent/JP6117251B2/en active Active
- 2013-02-26 BR BR112014019349A patent/BR112014019349A8/en not_active Application Discontinuation
- 2013-02-26 DK DK13707113.0T patent/DK2823314T3/en active
- 2013-02-26 IN IN7813DEN2014 patent/IN2014DN07813A/en unknown
- 2013-02-26 EP EP13707113.0A patent/EP2823314B1/en not_active Revoked
- 2013-02-26 ES ES13707113.0T patent/ES2631653T3/en active Active
-
2014
- 2014-07-29 ZA ZA2014/05610A patent/ZA201405610B/en unknown
- 2014-11-28 HK HK14112042.7A patent/HK1198556A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013131621A1 (en) | 2013-09-12 |
CN104126125B (en) | 2017-03-01 |
ES2631653T3 (en) | 2017-09-01 |
WO2013131621A8 (en) | 2014-06-12 |
RU2688168C2 (en) | 2019-05-20 |
BR112014019349A2 (en) | 2017-06-20 |
CN104126125A (en) | 2014-10-29 |
JP2015509596A (en) | 2015-03-30 |
ZA201405610B (en) | 2015-12-23 |
RU2014140608A (en) | 2016-04-27 |
EP2637023A1 (en) | 2013-09-11 |
US20150080246A1 (en) | 2015-03-19 |
HK1198556A1 (en) | 2015-05-15 |
EP2823314A1 (en) | 2015-01-14 |
EP3232201A1 (en) | 2017-10-18 |
BR112014019349A8 (en) | 2017-07-11 |
EP2823314B1 (en) | 2017-04-12 |
JP6117251B2 (en) | 2017-04-19 |
DK2823314T3 (en) | 2017-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN07813A (en) | ||
MX2013000674A (en) | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy. | |
AR098155A1 (en) | METHODS TO DIAGNOSTIC AND TREAT EOSYNOPHYL DISORDERS | |
MX2012001716A (en) | Biological markers for monitoring patient response to vegf antagonists. | |
MX2016006252A (en) | Treatment or prevention of pulmonary conditions with carbon monoxide. | |
MX2014011254A (en) | Drilling system failure risk analysis method. | |
WO2013160315A3 (en) | Genetic predictors of response to treatment with crhr1 antagonists | |
NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
RU2010145662A (en) | METHOD FOR PREDICTING THE RISK OF DEATH OF PATIENTS WITH CHRONIC HEART FAILURE | |
IN2012DN02058A (en) | ||
WO2014040891A3 (en) | Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation | |
WO2011150509A3 (en) | Diagnosing asthma based on pentraxin-3 | |
BR112013027080A2 (en) | Method and apparatus for characterizing integrity of process control equipment | |
WO2015036643A3 (en) | Marker for predicting metastasis of breast cancer | |
UA82125U (en) | Method for prediction of instrumental fractures in patietnts with false joints | |
GB201020071D0 (en) | Method | |
WO2014009055A9 (en) | Method and kit for predicting or monitoring the response of a cancer patient to chemotherapy, based on measuring the expression level of tmem45a gene. | |
MX2014002307A (en) | Method for predicting risk of hypertension associated with anti-angiogenesis therapy. | |
UA95606U (en) | METHOD OF FORECASTING FRAGMENT FRAGMENT | |
UA95605U (en) | METHOD OF FORECASTING FRAGMENT FRAGMENT | |
UA82685U (en) | Method for treatment of false joints of bones | |
UA96918U (en) | METHOD OF FORECASTING FRAGMENT FRAGMENT | |
UA95600U (en) | METHOD OF FORECASTING FRAGMENT FRAGMENT | |
Pillai et al. | A Pilot Study To Investigate The Proteomics Profile Of Asthmatic Patients With Varying Types Of Bronchitis | |
EP3360977A3 (en) | Mi-rna based treatment monitoring in multiple sclerosis |